Mercè Navarro-Llavat
A5011593256- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Diagnosis and treatment of tuberculosis
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Pregnancy and Medication Impact
- Autoimmune and Inflammatory Disorders
- Diverticular Disease and Complications
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Tuberculosis Research and Epidemiology
- Gastric Cancer Management and Outcomes
- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 and healthcare impacts
- Clostridium difficile and Clostridium perfringens research
- Reproductive System and Pregnancy
- Chronic Lymphocytic Leukemia Research
- Intraperitoneal and Appendiceal Malignancies
- Gastroesophageal reflux and treatments
- Medical research and treatments
- Pharmaceutical studies and practices
Hospital de Sant Joan Despí Moisès Broggi
2016-2025
Hospital Universitario Río Hortega
2024
Hospital Universitari Germans Trias i Pujol
2007-2013
The aims of this study were to assess the risk relapse after discontinuation anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), identify factors associated relapse, and evaluate overcome retreatment same anti-TNF those who relapsed.This was a retrospective, observational, multicenter study. IBD had been treated anti-TNFs whom these discontinued clinical remission achieved included.A total 1,055 included. incidence rate 19% 17% per patient-year...
The aims of this study were to determine the prevalence fatigue in patients with inflammatory bowel disease [IBD], identify factors associated and its severity, assess impact on quality life [QoL], evaluate relationship between sleep disorders.This was a prospective multicentre conducted at 22 Spanish centres. Consecutive followed IBD Units included. Fatigue evaluated Severity Scale [FSS] Impact [FIS]. Quality assessed using Questionnaire-Short Form [IBDQ-9] Pittsburgh Sleep Index [PSQI],...
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed clinical practice. We aimed to evaluate the durability, effectiveness, and safety UC real life.Patients included prospectively maintained ENEIDA registry, who received at least one intravenous dose due active [Partial Mayo Score [PMS]>2], were included. Clinical activity effectiveness defined based on PMS. Short-term response was assessed Week 16.A total 95...
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe main epidemiological and clinical characteristics at diagnosis evolution disease, explore use drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 Spain were included followed-up for 1 year. (3) Results: We identified 3611 incident cases during 108 hospitals...
Aim. The aim was to assess the impact of inflammatory bowel disease (IBD) and its treatment on fertility, pregnancy outcomes, breastfeeding. IBD is a chronic condition that usually diagnosed in young adulthood. Patients are often concerned about fertility outcomes. Methods. A structured questionnaire posted 850 adults with followed-up single center. Results. total 503 patients (59%) median age 40 years equally distributed for gender type returned questionnaire. Overall, 71% had 659 children,...
Abstract Background and Aims Clinical trials real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy safety profile. However, these data are scarcely available elderly patients. Therefore, we aim to assess the effectiveness of patients CD. Methods Elderly [>60 years old] from prospectively maintained ENEIDA registry treated due CD were included. Every patient was matched two controls under 60 age, according anti-tumour necrosis factor use smoking...
Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. aim this study was analyze and safety treatment with a second third anti-TNF drug after intolerance or failure previous in inflammatory bowel disease (IBD) patients. Methods We included patients diagnosed IBD from ENEIDA registry who received prior agent. Results A total 1122 were included. In short term, remission achieved 55% anti-TNF. incidence loss response 19% per...
Background: Intestinal infections have been claimed to precipitate or aggravate flares of inflammatory bowel disease (IBD). The reported incidence such among IBD patients varies between 9 and 13%, but only a few prospective studies conducted. Aims: To evaluate the intestinal by enteropathogens in with active IBD, their impact on clinical outcome, identify associated risk factors. Patients Methods: Consecutive admitted because relapse suspected onset were prospectively included. At...
Abstract Background Factors influencing the exposure to targeted therapies (biologics/JAKi), intestinal resections and hospitalisations in newly diagnosed IBD patients have been scarcely studied. Aim: To identify predictive factors of biologics/JAKi, surgeries, within first five years patients. Methods Prospective, population-based nationwide registry. Adult with [Crohn’s disease (CD), ulcerative colitis (UC) or unclassified (IBD-U)] during 2017 17 Spanish regions were included. Patients who...
Abstract Background Anti-TNF availability has been associated with a decrease of first intestinal resections in patients Crohn’s Disease (CD). However, few studies have evaluated the impact biological therapies medical management postoperative CD and its long-term outcomes. We aimed to assess time trends strategies for setting after resection rate second surgeries (surgical recurrence –sPOR-) through last three decades. Methods Adult who underwent ileocolic anastomosis between 1990 2020 at...
Abstract Background Postoperative recurrence (POR) in patients with Crohn’s disease (CD) can be prevented early postoperative use of thiopurines or anti-TNFs. However, the benefit medical prophylaxis has not been assessed long-term. We aimed to assess risk a second intestinal resection (surgical POR -sPOR-) for CD according prevention after first resection. Methods Adult who underwent ileocolic anastomosis between 2000 and 2020 had at least one year clinical follow-up, were identified from...
Abstract Background Anti–tumor necrosis factor agents (anti-TNFs) are efficacious at preventing the postoperative recurrence (POR) of Crohn disease, as demonstrated in 2 randomized controlled trials. However, real-life data for infliximab or adalimumab this setting scarce. Our aim was to assess both efficiency anti-TNFs early POR disease clinical practice and associated risk factors POR. Methods Patients whom were prescribed prevention within 3 months after ileocolonic resection who had an...
Abstract Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven clinical trials including patients clinical, endoscopic, and radiologic remission at the time withdrawal to make recommendations for practice. Aims Primary: compare rates 1 year who discontinue treatment vs. those continue treatment. Secondary objectives: know effect on relapse-free time, mucosal healing safety; identify predictive factors relapse. Methods...
We aim to describe the incidence and source of contagion COVID-19 in patients with IBD, as well risk factors for a severe course long-term sequelae. This is prospective observational study IBD included ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up 12 months. Results were compared data general population (National Centre Epidemiology Catalonia). A total 482 identified. Twenty-eight percent infected work environment, 48% by intrafamilial transmission, despite...
Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients. We aimed to compare rates of IFX-related IAEs and loss response [LOR] younger patients.Adult patients ENEIDA registry who had received a first course IFX were identified grouped into two cohorts regarding age at beginning treatment [over 60 years between 18 50 years]. The LOR...
Markers that allow for the selection of tailored treatments individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was describe trends in real-life treatment usage. For this purpose, from ENEIDA registry who received their first targeted IBD (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis Machine Learning models performed. The study included 10,009 [71% Crohn’s disease (CD) 29% ulcerative colitis (UC)]. In CD,...
Background and objectives Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) immunomodulators who withdraw anti-TNF treatment versus those maintain it. Secondary evaluate effect withdrawal on relapse-free time, endoscopic radiological activity, safety, quality life work productivity; identify predictive factors for relapse. Design Prospective, quadruple-blind, multicentre, randomised, controlled...
INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions patients POR. METHODS: Multicenter, retrospective, study who underwent therapy for POR (Rutgeerts score > i1). Treatment outcomes were assessed by findings last ileocolonoscopy performed after initiated. Endoscopic...